Document Detail

Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.
MedLine Citation:
PMID:  12225717     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The goal of this study was to identify the factors responsible for embolic complications of direct current (DC) cardioversion of atrial arrhythmias. BACKGROUND: Direct current cardioversion of atrial fibrillation (AF) carries a risk of thromboembolism, which is reduced, but not eliminated, by anticoagulation. The risk of embolism after conversion of atrial flutter is believed to be lower. No series to date has included enough patients receiving anticoagulants or enough patients with atrial flutter to estimate the risk in these groups. METHODS: We reviewed the case records of 1,950 patients who underwent 2,639 attempts at DC cardioversion. RESULTS: Cardioversion was performed within two days of the apparent onset of the arrhythmia in 443 episodes, 352 without subsequent prolonged anticoagulation with one embolic complication. Cardioversion was preceded by warfarin therapy for > or = 3 weeks in 1,932 instances. No embolic complication occurred in 779 attempts performed with an international normalized ratio (INR) of > or = 2.5 (95% confidence limits 0% to 0.48%). Of 756 cases in which the INR was <2.5 or was not measured before conversion, nine were complicated by thromboembolism. Embolism was significantly more common at an INR of 1.5 to 2.4 than at an INR > or = 2.5 (0.93% vs. 0%, p = 0.012). The incidence of embolism after conversion of atrial flutter or tachycardia was similar to that after cardioversion of AF (0.72% vs. 0.46%, p = NS). CONCLUSIONS: The INR should be > or = 2.5 at the time of cardioversion if the duration of AF is uncertain or >2 days. Cardioversion of atrial flutter presents similar risks and requires similar anticoagulation.
Mark M Gallagher; Brian J Hennessy; Nils Edvardsson; Ceara M Hart; Muriel S Shannon; Owen A Obel; Naab M Al-Saady; A John Camm
Related Documents :
17661767 - The clinical noncompliance of oral sotalol/magnesium for prophylactic treatment of atri...
3233807 - Necropsy study of right atrial appendage: morphology and quantitative measurements.
17161267 - A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic dru...
14690727 - Prevention of atrial fibrillation after cardiac valvular surgery by epicardial, biatria...
20808247 - Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric p...
24299727 - A multicenter prospective non-randomized controlled clinical trial to prove neurotherap...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  40     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-09-12     Completed Date:  2002-09-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  926-33     Citation Subset:  AIM; IM    
Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / administration & dosage*
Atrial Fibrillation / therapy*
Atrial Flutter / therapy*
Electric Countershock / adverse effects*,  methods
Embolism / etiology*
Middle Aged
Warfarin / administration & dosage
Reg. No./Substance:
0/Anticoagulants; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irreg...
Next Document:  Relationship between obesity, insulin resistance, and coronary heart disease risk.